This website is designed to help potential applicants find resources related to the funding opportunity announcements (FOAs) in support of CP-CTNet.
Funding Opportunity Announcement (FOA) - active 6/28/19-8/30/19
Number: RFA-CA-19-031
Funding Opportunity Title: Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
Announcement Type: Reissue of RFA-CA-18-029 (see pre-application webinar information for RFA-CA-029, no longer active, below)
Companion Funding Opportunity: None
See: Frequently Asked Questions (FAQs)
Funding Opportunity Purpose
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet), for which the goals are as follows:
- Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials;
- Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.
- Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
Background
The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data. The DMACC will support the CP-CTNet Sites and coordinate trans-Network activities with the following specific responsibilities:
(i) centralized data management and data reporting,
(ii) clinical trials auditing, and
(iii) administrative and logistical coordination across CP-CTNet.
Link to the CP-CTNet: Concept presentation to NCI Board of Scientific Advisors (BSA)
- Slides (PDF, 437 KB)
- NIH VideoCast (presentation between 02:15:50 and 02:48:30)
Program Information and Resources for Applicants
Information about 2012 Consortia Program
- Phase 0/I/II Cancer Prevention Clinical Trials Program
- 2012 Consortia Trials Standard Operating Procedures
- 2012 Consortia Trials Instructions and Tools
Information and Resources for Centralized Data Management and Reporting
- Medidata Rave® Data Capture & Management
- DataIntegration Program
- Accrual Quality Improvement and Tracking Program (AQuIP)
- Cancer Data Standards Repository (caDSR)
DCP Contract Resources / Programs Supporting CP-CTNet
- NCI Central Institutional Review Board (CIRB)
- Regulatory Support Program
- Drug Repository Program
- Biorepository Program
- Protocol Information Office (PIO) Support Program
Administrative and Logistical Coordination
Annual Investigators' — Site Coordinators' Opportunity for Research Excellence (I-SCORE) Meeting Information
Pre-application Webinar Cancer Prevention Clinical Trials Network (FOA's no longer active)
Slides and Recordings and FAQs
Slide Presentation: Potential Applicant Webinar: Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Site (UG1)
- Slide Recording (YouTube Video, 00:44:48)
- RFA-CA-18-029 FAQs
Slide Presentation: Potential Applicant Webinar: Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Coordinating Center (DMACC)
- Slide Recording (YouTube Video, 00:39:58)
- RFA-CA-18-030 FAQs